Khiron Life Sciences Corp (CVE:KHRN) Participates In 1st Ever Cowen LATAM Conference Panel

Benjamin A. Smith

Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) took additional steps in legitimizing its market segment to institutional investors yesterday. The company was one of four licensed producers to present on Cowen’s Toronto Cannabis Summit LATAM panel, which highlighted the area’s growing regional importance in the global cannabis domain.

Khiron Life Sciences presented along with Landsteiner, Northern Swan and PharmaCielo in Cowen’s first ever LATAM-focused cannabis panel. Previously, panel discussions were restricted to North American LPs and specific segment operators within the sector. The symposium particularly significant since Cowen is regarded as the preeminent U.S. investment bank in the industry, seizing the initiative well before the Banking and STATES Act have completed the legislative process. Cowen’s lead cannabis analyst—Vivian Azer—is perhaps the most highly regarded analyst in the space; currently, she’s ranked 75th out of 5,182 analysts, according to TipRanks.

In turn, it wouldn’t be unfair to say yesterday’s events marked a preliminary step in Khiron’s goal to receive broader coverage within the Tier-1 investment community—although several small and non-public LPs also participated.

The discussion centered around policy and market trends specific to the LATAM marketplace, in which 639 million people reside. Khiron’s contribution to the discourse was distinct, as they are operationally unique from all the licensed producers operating in Canada today. Specifically in Latin America, where the company is steering clear of low-margin mass cannabis cultivation followed by peer Pharmacielo Ltd. and the Tier-1 Canadian LP subsidiaries.

Yesterday, Khiron CEO Alvaro Torres talked about the company’s current non-cultivation patient & distribution model, the oncoming CDB-infused marketplace, its Kuida cosmaceutical product line, and more. With its anticipated acquisition of NettaGrowth due to be completed by the end of June 2019, and the recent introduction of Kuida into Colombia’s leading drugstore chain, there was plenty to discuss.

Beyond specific company matters, Khiron bestowed the panel with prescient insights on LATAM cannabis markets, regulation and policy. Long regarded as a regional influencer with heavyweights like Alvaro Torres and Vicente Fox guiding the company, investors eagerly digested what Khiron had to say. We expect Cowen’s foray into LATAM-specific market coverage won’t be its last.

Midas Letter will have further coverage as events warrant.

Benjamin A. Smith

Benjamin A. Smith

Ben is a research analyst and capital markets professional with nearly 20 years of experience. His areas of expertise are broad-based, and include extensive knowledge of macro economics, stock/derivative trading, commodity complexes, cryptocurrencies and technical/quant analysis. He also maintains an particular affinity for U.S. politics and the macro-regulatory environment facing...
More Info...

[email protected] |

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Free Newsletter,
Priceless Content.

Be the first to hear from Midas Letter on all things Cannabis.